Company intelligence / Profile preview

Huixin Bio

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Shenzhen Huixin Biomedical Technology ("Huixin Bio") develops automated systems for the separation and purification of exosomes, aiming to standardize extraction with high recovery rates. The company focuses on early cancer diagnosis and treatment using these technologies. As of June 2025, there are no active clinical trials listed on ClinicalTrials.gov for their products. The company has received several innovation awards in China but has not yet reported clinical results or commercialized therapeutics.

Therapeutic areas: OncologyOther
Modalities: Exosome-based therapy (diagnostic and therapeutic products)Device (automated exosome purification systems)
Industry: Molecular Diagnostics

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Huixin Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huixin Bio.

Explore the full profile